Literature DB >> 32369451

Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.

Nesrine Boukhedouni1, Christina Martins1, Anne-Sophie Darrigade1,2, Claire Drullion1, Jérôme Rambert3, Christine Barrault4, Julien Garnier4, Clément Jacquemin1, Denis Thiolat1, Fabienne Lucchese1, Franck Morel5, Khaled Ezzedine6, Alain Taieb2, François-Xavier Bernard4, Julien Seneschal1,2, Katia Boniface1.   

Abstract

Loss of melanocytes is the pathological hallmark of vitiligo, a chronic inflammatory skin depigmenting disorder induced by exaggerated immune response, including autoreactive CD8 T cells producing high levels of type 1 cytokines. However, the interplay between this inflammatory response and melanocyte disappearance remains to be fully characterized. Here, we demonstrate that vitiligo skin contains a significant proportion of suprabasal melanocytes, associated with disruption of E-cadherin expression, a major protein involved in melanocyte adhesion. This phenomenon is also observed in lesional psoriatic skin. Importantly, apoptotic melanocytes were mainly observed once cells were detached from the basal layer of the epidermis, suggesting that additional mechanism(s) could be involved in melanocyte loss. The type 1 cytokines IFN-γ and TNF-α induce melanocyte detachment through E-cadherin disruption and the release of its soluble form, partly due to MMP-9. The levels of MMP-9 are increased in the skin and sera of patients with vitiligo, and MMP-9 is produced by keratinocytes in response to IFN-γ and TNF-α. Inhibition of MMP-9 or the JAK/STAT signaling pathway prevents melanocyte detachment in vitro and in vivo. Therefore, stabilization of melanocytes in the basal layer of the epidermis by preventing E-cadherin disruption appears promising for the prevention of depigmentation occurring in vitiligo and during chronic skin inflammation.

Entities:  

Keywords:  Autoimmune diseases; Cytokines; Dermatology; Inflammation; Skin

Mesh:

Substances:

Year:  2020        PMID: 32369451      PMCID: PMC7308056          DOI: 10.1172/jci.insight.133772

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  57 in total

1.  Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Trees A M Dellemijn; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Florry A Vyth-Dreese; Rosalie M Luiten
Journal:  J Invest Dermatol       Date:  2009-02-26       Impact factor: 8.551

Review 2.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

3.  Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B.

Authors:  Deep Joshipura; Abdulaziz Alomran; Pedro Zancanaro; David Rosmarin
Journal:  J Am Acad Dermatol       Date:  2018-02-10       Impact factor: 11.527

4.  Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: A survey study.

Authors:  Séverine Amico; Thomas Barnetche; Laure Dequidt; Antoine Fauconneau; Emilie Gérard; Lucile Boursault; Katia Boniface; Anne-Sophie Darrigade; Julien Seneschal
Journal:  J Am Acad Dermatol       Date:  2020-02-14       Impact factor: 11.527

Review 5.  Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade.

Authors:  Jennifer Vandooren; Philippe E Van den Steen; Ghislain Opdenakker
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-04-02       Impact factor: 8.250

Review 6.  Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments.

Authors:  Justin M David; Ayyappan K Rajasekaran
Journal:  Cancer Res       Date:  2012-06-01       Impact factor: 12.701

Review 7.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

Review 8.  The role of tumor necrosis factor-α in the pathogenesis of vitiligo.

Authors:  Carlos R Camara-Lemarroy; Julio C Salas-Alanis
Journal:  Am J Clin Dermatol       Date:  2013-10       Impact factor: 7.403

9.  IFN-γ signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation.

Authors:  Vivek T Natarajan; Parul Ganju; Archana Singh; Vinaya Vijayan; Kritika Kirty; Shalini Yadav; Shraddha Puntambekar; Sonali Bajaj; Prachi P Dani; Hemanta K Kar; Chetan J Gadgil; Krishnamurthy Natarajan; Rajni Rani; Rajesh S Gokhale
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-28       Impact factor: 11.205

10.  DDR1 promotes E-cadherin stability via inhibition of integrin-β1-Src activation-mediated E-cadherin endocytosis.

Authors:  Hong-Ru Chen; Yi-Chun Yeh; Ching-Yi Liu; Yu-Ting Wu; Fang-Yu Lo; Ming-Jer Tang; Yang-Kao Wang
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

View more
  12 in total

1.  Increased expression of Myosin X contributes to the metastasis in patients with laryngeal squamous cell carcinoma.

Authors:  Gang Deng; Tie-Jun Fu; Cui-Ping Liu
Journal:  Mol Genet Genomics       Date:  2022-08-11       Impact factor: 2.980

2.  Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro.

Authors:  Jie Dong; Xuan Huang; Li-Ping Ma; Fei Qi; Si-Nian Wang; Zi-Qin Zhang; Shi-Nan Wei; Ling Gao; Fang Liu
Journal:  Dose Response       Date:  2022-05-31       Impact factor: 2.623

Review 3.  Vitiligo, From Physiopathology to Emerging Treatments: A Review.

Authors:  Laure Migayron; Katia Boniface; Julien Seneschal
Journal:  Dermatol Ther (Heidelb)       Date:  2020-09-19

Review 4.  Translational Research in Vitiligo.

Authors:  Erica L Katz; John E Harris
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

Review 5.  Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective.

Authors:  Katia Boniface; Thierry Passeron; Julien Seneschal; Meri K Tulic
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 6.  Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.

Authors:  Fei Qi; Fang Liu; Ling Gao
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

7.  MCP mediated active targeting calcium phosphate hybrid nanoparticles for the treatment of orthotopic drug-resistant colon cancer.

Authors:  Shaobo Bai; Yang Sun; Ying Cheng; Weiliang Ye; Chenchao Jiang; Miao Liu; Qifeng Ji; Bangle Zhang; Qibing Mei; Daozhou Liu; Siyuan Zhou
Journal:  J Nanobiotechnology       Date:  2021-11-17       Impact factor: 10.435

Review 8.  Current Concepts of Vitiligo Immunopathogenesis.

Authors:  Nika Hlača; Tina Žagar; Marija Kaštelan; Ines Brajac; Larisa Prpić-Massari
Journal:  Biomedicines       Date:  2022-07-08

Review 9.  Mechanisms of melanocyte death in vitiligo.

Authors:  Jianru Chen; Shuli Li; Chunying Li
Journal:  Med Res Rev       Date:  2020-11-17       Impact factor: 12.944

10.  LncRNA FENDRR in Carcinoma-Associated Fibroblasts Regulates the Angiogenesis of Oral Squamous Cell Carcinoma Through the PI3K/AKT Pathway.

Authors:  Yuming Xu; Erhui Jiang; Zhe Shao; Zhengjun Shang
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.